1. Introduction
A novel Coronavirus, severe acute respiratory syndrome (SARS-CoV-2) has emerged in December 2019 in Wuhan China and caused a human pandemic resulting to more than 500,000,000 infection cases and around 6,200,000 deaths [1] [2] [3]. The global incidence of the infection is still growing as well as number of deaths [3]. Although molecular diagnostic tests were developed rapidly, serological studies are still lacking and yet extremely needed [4]. According to WHO currently there is a need to conduct seroprevalence studies in different countries, which will allow to make inferences for future strategic decisions and understand the real incidence of infection in different countries [5]. Currently seroprevalence studies are initiated in many countries [4] [5] [6]. Serological assays are approved by FDA and EUA and are widely used [4] [6]. In all countries the initial epidemiological surveillance was focused on symptomatic cases, so the proportion of asymptomatic cases to the pandemic is not well studied [2] [5]. PCR test has an ability to detect the virus from upper respiratory system mainly for during 2 weeks of viral shedding, after which the virus can be detected with serological methods only [5] [7] [8]. Coronavirus antibodies usually become detectable after 1st week of symptom onset [4] [5]. There are various theories regarding the fact that during the third week the infectiousness declines as patient becomes immune, however additional studies are needed [5] [7]. In Armenia the first case of coronavirus was confirmed on the 1st of March 2020, after which the daily incidence has been rising daily [9]. There is a need to understand IgG prevalence among population taking into account severity of infection, medication taken during treatment and other factors in anamnesis, to be able to make informed decisions regarding public health prevention strategies [5] [7] [8]. This study will serve as a basis for understanding of kinetics of IgG titer changes in blood of population may provide valuable information not only for policy makers but also for scientists working on development of vaccine and testings [10]. [11] There is a controversial opinion in literature regarding smoking status and COVID-19, therefore in the scope of current study, the difference in hospitalization status among smokers and non-smokers was also explored, as several studies published previously highlighted the protective effect of smoking status in the likelihood of being hospitalized with COVID-19 [12] [13].
2. Objectives
Current research aims to determine the IgG antibody levels following COVID- 19 infection. Nevertheless, the study will help to elucidate the fraction of asymptomatic or pre-symptomatic/subclinical infections in the population and understand the main risk factors for infection complication.
Research also aims to explore the difference of antibody titers among symptomatic vs. asymptomatic patients. The difference of antibody titers will also be explored from the prospective of antiviral drugs, antibiotics taken and vaccination anamnesis. The multivariate analysis will be conducted.
One of the research questions will be related with smoking status and coronavirus infection complications.
The study will also explore how the pre-existing chronic conditions are related to the infection complications.
Current research aims to describe COVID-19 infection among large sample of population. This study will also serve for the baseline information to further evaluate the difference of the symptoms during different periods of pandemics caused by various mutated strains.
Starting from very early stages of coronavirus pandemics various assumptions existed regarding natural immunity [14] [15] [16] [17] [18]. We hope to be able to answer the question about the determinants of natural immunity. We assume that many countries may do similar studies, however this study will be able to describe the situation among Armenian patients. The gathered data will give us opportunity to make preliminary analysis on various associations of IgG titers and different factors, so it will help to elucidate some important gaps in existing knowledge and generate hypothesis for future research.
The study was approved by Ethics Board of “EcoSense” diagnostic medical center. All participants were given an informed consent.
3. Research Methodology
The cross-sectional study was performed with convenience sampling. The exclusion criteria was having COVID-19 positive test during last 14 days prior participation in the study. 1573 individuals who turned to any of the branches of “EcoSense” laboratories were offered to participate in the study by taking a blood sample and filling the interviewer administered questionnaire regarding the COVID-19 status, symptoms, exposure history, disease history, pre-existing chronic conditions, medication and the vaccination history (see Appendix). 837 agreed to participate in the study. The total duration of the study was 12 months. On the time of testing all the participants were recovered in less than 3 months period.
The high-quality reagents manufactured in Germany (NovaTec) were used. The testing was performed in ‘’EcoSense’’ diagnostic center in capital of Armenia: Yerevan. As the center also has 7 functioning branches in regions of Armenia as well as in the Republic of Artsakh the laboratory services are accessible not only for participants living in Yerevan, therefore it was possible to achieve a good geographic representativeness.
EcoSense is the only diagnostic center in Armenia having ISO 9001:2015 international certificate issued by TÜVRheinland (ID 9108658675) in 2020.
Blood samples were centrifuged and sent to the central laboratory in Yerevan. The ELISA equipment (Thermo Scientific Multiskan FC) has been used for analyzing. The data has been entered to SPSS and analyzed. The following ELISA test kits have been used NovaTec SARS-CoC-2 (COVID-19) IgG COVG940 96 Determinations. Descriptive, correlation as well as linear regression analysis was used to answer the research questions. Data was entered and analyzed using statistical package SPSS 22.
4. Results
Overall 1573 testing was performed 837 of subjects agreed to participate in the interview. 57.5% were females. 24.1% of participants had laboratory confirmed COVID-19 but by the time of interview were already recovered. 212 (25.3%) participants had positive IgG levels, among 126 (15.1%) participants IgG levels were in the grey zone. Out of PCR confirmed cases only 58.7% had positive IgG levels and 3.9% IgG level was in the grey zone.
4.9% of participants was previously symptomatic, however were not tested to confirm COVID-19 infection. Out of all previously symptomatic but non-con- firmed cases 31.5% had positive IgG levels.
Table 1 illustrates the prevalence of symptoms among all participants, among participants with previously confirmed PCR test and participants with positive IgG titer.
10.5% of patients had some level of symptoms persistence during participation in the study. 13.7% of participants with positive IgG titer did not have any symptoms, 3.8% had only loss of sense of taste and anosmia.
Headache was the most common symptom among participants (37.2% among all participants and 53.1% among participants who previously had positive CO- VID-19 PCR test). Second most common symptom was anosmia (23.7% among all participants and 48.9% among participants who previously had positive CO- VID-19 PCR test).
5.4% of participants mentioned previous hospitalization due to COVID-19, 71 (8.5%) mentioned being diagnosed with pneumonia and 24 (2.9%) participants mentioned being admitted to ICU 20 mentioned receiving oxygen therapy and 4 (0.5%) of the participants mentioned receiving an artificial ventilation of lungs. 26 of the participants mentioned being pregnant gestation age varied from 6 - 35 weeks.
19.4% of participants mentioned being a smoker. 6.8% of them previously had positive COVID-19 PCR test. However, among all smokers only 14.2% had positive IgG, 13.0% were in the grey zone.
41.1% of patients mentioned taking antibiotics during last one year period and 30.5% mentioned history of taking antiviral medication.
The symptoms quantity was summed up to a symptom score. In order to identify the association between symptoms quantity and IgG levels the correlation and linear regression analysis were performed. There was a weak positive correlation between symptom sum score and IgG titers. The Correlation coefficient was 0.273, p < 0.05, R2 = 0.075. Table 2 presents linear regression analysis results.
The overall regression model was significant F(1, 711) = 57.45, P < 0.01, R2 = 0.075. The obtained results for the linear regression analysis indicate that the number of symptoms patients have is a significant predictor for IgG level.
Table 2. Linear regression analysis.
aPredictors: (Constant), IgG1. *R is a correlation between predicted values and observed values.
aDependent Variable: symptomsum; bPredictors: (Constant), IgG1; *Df is Degree of Freedom; **F test of a null hypothesis.
aDependent Variable: symptomsum.
5. Discussion
Unfortunately, there are no other seroprevalence studies to our knowledge conducted in Armenia, so we could compare our results. However, it was obvious that the numbers of COVID-19 cases are much greater than it was reported, as 31.5% had positive titer without previously having a positive COVID-19 test. This finding is comparable to the studies done in other countries [14] [15].
The prevalence of symptom persistence is relevant to the existing studies [19]. Though it is difficult to evaluate as different participants participated in testing in different time interval after recovery. Further studies are required to assess the exact burden of persistent symptoms and factors associated with those symptoms.
According to our findings the most common symptom among participants was headache which contradicts other studies where the most common reported symptom was fever [8] [20] [21].
Current study has several limitations. The main limitation is sampling by convenience design, as our sample is consisting of individuals who turned to examination voluntarily, so it may consist of individuals who have previously had symptoms and are concerned about COVID-19. There is an overrepresentation of female participants in our study. Our study also cannot be quite generalized for vulnerable social groups of population, as the data was collected from the tests performed for payment. Even though the samples were arriving from different parts of Armenia, however there is no even distribution from each region as the majority of participants are from Yerevan. Therefore, the study results cannot be generalized to entire Armenia. Another important limitation is the fact that the evaluation of symptoms is based on self-reported data, which may involve some recall bias.
Scaling up the population wide serological testing in Armenia can help with evidence based public health decision making [15].
For further research we recommend to perform a follow up study and to assess antibody kinetics over time and the incidence of reinfection with COVID-19 in the year of 2021 in cases of non-vaccinated as well as vaccinated individuals. The effects of smoking status, as well as different chronic conditions on COVID- 19 shall be studied further.
Appendix